Table 3.
Number of immunoreactive linear epitopes identified in human EBOV (1:12,800) and BOMV (1:800) reactive serum samples compared to a negative human serum sample by gene and overall for all six ebolaviruses and Marburg virus
| EBOV Presumptive Positive Patient | BOMV Presumptive Positive Patient | Negative Human | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peptide | NP | VP35 | VP40 | GP | VP30 | VP24 | L | Tot | NP | VP35 | VP40 | GP | VP30 | VP24 | L | Tot | NP | VP35 | VP40 | GP | VP30 | VP24 | L | Tot |
| EBOV | 2 | 1 | 3 | 3 | 9 | 9 | 4 | 10 | 4 | 16 | 43 | |||||||||||||
| BOMV | 4 | 2 | 1 | 4 | 11 | 10 | 6 | 3 | 10 | 3 | 2 | 18 | 52 | 1 | 1 | 1 | 3 | |||||||
| SUDV | 1 | 1 | 2 | 4 | 8 | 1 | 12 | 5 | 16 | 42 | 1 | 1 | 2 | |||||||||||
| BDBV | 2 | 3 | 1 | 4 | 10 | 7 | 1 | 10 | 2 | 15 | 35 | |||||||||||||
| TAFV | 3 | 1 | 2 | 6 | 9 | 3 | 10 | 2 | 18 | 42 | ||||||||||||||
| REST | 3 | 2 | 4 | 9 | 9 | 11 | 3 | 18 | 41 | 2 | 3 | 5 | ||||||||||||
| MARV | 2 | 1 | 3 | 9 | 4 | 13 | 3 | 22 | 51 | 2 | 1 | 3 | ||||||||||||